Log in

NYSE:ARA - American Renal Associates Stock Price, Forecast & News

$8.90
-0.12 (-1.33 %)
(As of 02/19/2020 01:38 AM ET)
Today's Range
$8.71
Now: $8.90
$9.07
50-Day Range
$8.42
MA: $9.36
$10.42
52-Week Range
$5.48
Now: $8.90
$14.10
Volume22,400 shs
Average Volume67,341 shs
Market Capitalization$290.21 million
P/E RatioN/A
Dividend YieldN/A
Beta2.19
American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of June 30, 2018, it owned and operated 233 dialysis clinics in partnership with 400 nephrologist partners treating approximately 16,000 patients in 26 states and the District of Columbia. Read More…

Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone978-922-3080

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$805.78 million
Cash Flow$1.95 per share
Book Value$3.38 per share

Profitability

Net Income$-28,770,000.00

Miscellaneous

Employees4,932
Market Cap$290.21 million
Next Earnings DateN/A
OptionableOptionable

Receive ARA News and Ratings via Email

Sign-up to receive the latest news and ratings for ARA and its competitors with MarketBeat's FREE daily newsletter.


American Renal Associates (NYSE:ARA) Frequently Asked Questions

What is American Renal Associates' stock symbol?

American Renal Associates trades on the New York Stock Exchange (NYSE) under the ticker symbol "ARA."

How were American Renal Associates' earnings last quarter?

American Renal Associates Holdings Inc (NYSE:ARA) released its earnings results on Tuesday, August, 7th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.17 by $0.03. The company had revenue of $217.18 million for the quarter, compared to the consensus estimate of $203.70 million. American Renal Associates had a negative net margin of 1.75% and a positive return on equity of 23.16%. View American Renal Associates' Earnings History.

What price target have analysts set for ARA?

5 brokers have issued 12 month target prices for American Renal Associates' shares. Their forecasts range from $7.00 to $12.00. On average, they anticipate American Renal Associates' stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 12.4% from the stock's current price. View Analyst Price Targets for American Renal Associates.

What is the consensus analysts' recommendation for American Renal Associates?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for American Renal Associates in the last year. There are currently 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for American Renal Associates.

Has American Renal Associates been receiving favorable news coverage?

News coverage about ARA stock has been trending positive this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. American Renal Associates earned a daily sentiment score of 2.8 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. View News Stories for American Renal Associates.

Who are some of American Renal Associates' key competitors?

What other stocks do shareholders of American Renal Associates own?

Based on aggregate information from My MarketBeat watchlists, some companies that other American Renal Associates investors own include Akorn (AKRX), Collegium Pharmaceutical (COLL), Exelixis (EXEL), Amicus Therapeutics (FOLD), KemPharm (KMPH), Madrigal Pharmaceuticals (MDGL), Mylan (MYL), Pattern Energy Group (PEGI), Catalyst Pharmaceuticals (CPRX) and Fate Therapeutics (FATE).

Who are American Renal Associates' key executives?

American Renal Associates' management team includes the folowing people:
  • Mr. Joseph A. Carlucci, Co-Founder, CEO & Chairman (Age 65)
  • Mr. Syed T. Kamal, Founder, Pres & Director (Age 66)
  • Mr. Mark C. Herbers, Interim CFO & Interim Chief Accounting Officer (Age 64)
  • Dr. Don E. Williamson, Exec. VP & COO (Age 56)
  • Mr. Richard Pacheco CFE, AVA, MBA, VP of Admin.

When did American Renal Associates IPO?

(ARA) raised $161 million in an initial public offering (IPO) on Thursday, April 21st 2016. The company issued 7,500,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Barclays and Goldman Sachs acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

Who are American Renal Associates' major shareholders?

American Renal Associates' stock is owned by a number of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (3.18%), State Street Corp (1.07%), California Public Employees Retirement System (0.23%), Bank of New York Mellon Corp (0.22%), Strs Ohio (0.18%) and DekaBank Deutsche Girozentrale (0.18%). View Institutional Ownership Trends for American Renal Associates.

Which major investors are selling American Renal Associates stock?

ARA stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP, California Public Employees Retirement System, Spark Investment Management LLC, Strs Ohio, Bank of America Corp DE, Goldman Sachs Group Inc. and Bank of New York Mellon Corp. View Insider Buying and Selling for American Renal Associates.

Which major investors are buying American Renal Associates stock?

ARA stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, DekaBank Deutsche Girozentrale, State Street Corp, Financial Advisory Corp UT ADV, AQR Capital Management LLC, Tsfg LLC, Dynamic Technology Lab Private Ltd and Jefferies Group LLC. View Insider Buying and Selling for American Renal Associates.

How do I buy shares of American Renal Associates?

Shares of ARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is American Renal Associates' stock price today?

One share of ARA stock can currently be purchased for approximately $8.90.

How big of a company is American Renal Associates?

American Renal Associates has a market capitalization of $290.21 million and generates $805.78 million in revenue each year. American Renal Associates employs 4,932 workers across the globe.View Additional Information About American Renal Associates.

What is American Renal Associates' official website?

The official website for American Renal Associates is http://www.americanrenal.com/.

How can I contact American Renal Associates?

American Renal Associates' mailing address is 500 CUMMINGS CENTER SUITE 6550, BEVERLY MA, 01915. The company can be reached via phone at 978-922-3080 or via email at [email protected]


MarketBeat Community Rating for American Renal Associates (NYSE ARA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  199 (Vote Outperform)
Underperform Votes:  230 (Vote Underperform)
Total Votes:  429
MarketBeat's community ratings are surveys of what our community members think about American Renal Associates and other stocks. Vote "Outperform" if you believe ARA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel